European Investment Bank Provides EUR400 Million Loan to Fresenius for R&D and Capacity Expansion Across the EU

Strategic Insights -

The European Investment Bank has extended a EUR400 million loan to Fresenius, a global healthcare company, to support its research and development (R&D) activities and capacity expansion in Europe. This loan will enable Fresenius to increase the availability of innovative medicines and biosimilars across the continent. The financing demonstrates the EIB's commitment to high-quality and affordable healthcare in Europe. This loan is a key component of Fresenius' # FutureFresenius agenda, which aims to strengthen its European R&D activities and manufacturing capabilities.

Key Takeaways:

  • The European Investment Bank (EIB) has provided a EUR400 million loan to Fresenius to support R&D and capacity expansion in Europe.
  • The loan will enable Fresenius to increase the availability of innovative medicines and biosimilars across the EU.
  • The EIB-backed investments aim to strengthen the resilience of pharmaceutical production in the EU, contribute to security of supply, and provide financial relief to European healthcare systems.
  • Fresenius will use the financing to support expansion of Fresenius Kabi's manufacturing of medical products and biosimilars in European countries.
  • Almost 70% of prescriptions in Europe are for generic drugs, which represent around 20% of pharmaceutical costs, according to IQVIA research.
  • Fresenius has invested over EUR1 billion in European manufacturing over the last 5 years to meet European demand.
  • The EIB has provided over EUR22 billion in financing for the health and life sciences sector, including EUR4 billion in countries outside the EU.
  • The EIB has backed long-term innovation investments by Fresenius for around 20 years.
  • Sara Hennicken, CFO of Fresenius, emphasized the importance of the loan, stating it is "a valued recognition of our contribution to a healthy European future."
  • Nicola Beer, Vice President of the EIB, highlighted the EIB's commitment to accessible, high-quality healthcare throughout Europe, and its role in delivering innovative, affordable solutions for millions of patients.

Statistics:

  • EUR400 million: The value of the EIB loan to support Fresenius' R&D and capacity expansion in Europe.
  • 70%: The proportion of prescriptions in Europe for generic drugs, according to IQVIA research.
  • 20%: The proportion of pharmaceutical costs in Europe attributed to generic drugs, according to IQVIA research.
  • EUR1 billion: The amount invested by Fresenius in European manufacturing over the last 5 years.
  • 20 years: The duration of the EIB's support for Fresenius' long-term innovation investments.
  • EUR22 billion: The total value of EIB financing for the health and life sciences sector, including EUR4 billion in countries outside the EU.
  • 176,000: The number of Fresenius employees worldwide.
  • EUR21.5 billion: The annual revenue generated by Fresenius in the 2024 fiscal year.
  • 26 million: The number of patients treated annually by Fresenius Helios, the leading private hospital operator in Germany and Spain.

Sources:

  • European Investment Bank. (2025, 326). Fresenius receives a EUR400 million EIB loan to support R&D, innovation and capacity expansion across the EU.
  • Fresenius SE & Co. KGaA. (2024). Annual Report.
  • IQVIA. (2023). European Pharmaceutical Market Report.
  • European Investment Bank Group. (2024). Annual Report.